Enterprise Therapeutics' Phase 2 Trial for Cystic Fibrosis Drug ETD001 Shows Promising Results
Enterprise Therapeutics Ltd has announced successful results from its Phase 2 clinical trial for ETD001, an investigational inhaled epithelial sodium channel (ENaC) blocker designed to treat cystic fibrosis (CF). The trial demonstrated a statistically significant improvement in lung function for patients who do not benefit from CFTR modulators. Conducted across sites in the UK, Germany, France, and Italy, the trial involved participants with the highest unmet medical need. The results showed a 3.4% improvement in percent predicted forced expiratory volume in 1 second (ppFEV1) compared to placebo, with ETD001 being well-tolerated. The trial was divided into two parts, assessing safety and efficacy over a 28-day period. Enterprise plans to advance to longer duration Phase 2b trials and explore ETD001's efficacy alongside CFTR modulators. 
